|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/12/22 Cell MedX Corp. 10-Q 11/30/21 54:2.4M Empire Stock Transf… Inc |
Document/Exhibit Description Pages Size
1: 10-Q Cell Medx Corp. - Form 10-Q SEC Filing HTML 452K
2: EX-10.42 Loan Agreement October 7, 2021 HTML 20K
3: EX-10.43 Loan Agreement October 26, 2021 HTML 20K
4: EX-10.44 Loan Agreement November 24, 2021 HTML 19K
5: EX-10.45 Loan Agreement November 29, 2021 HTML 19K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 18K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 18K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 16K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 16K
15: R1 Document and Entity Information HTML 64K
16: R2 Condensed Consolidated Balance Sheets HTML 94K
17: R3 Condensed Consolidated Balance Sheets - HTML 22K
Parenthetical
18: R4 Condensed Consolidated Statements of Operations HTML 81K
19: R5 Condensed Consolidated Statement of Stockholders' HTML 69K
Deficit
20: R6 Condensed Consolidated Statements of Cash Flows HTML 82K
21: R7 Organization and Nature of Operations HTML 23K
22: R8 Related Party Transactions Disclosure HTML 34K
23: R9 Other Current Assets Disclosure HTML 18K
24: R10 Equipment Disclosure HTML 24K
25: R11 Revenue Disclosure HTML 27K
26: R12 Notes and Advances Payable Disclosure HTML 41K
27: R13 Share Capital Disclosure HTML 45K
28: R14 Related Party Transactions Disclosure: Schedule of HTML 25K
Amounts Due to Related Parties (Tables)
29: R15 Related Party Transactions Disclosure: Schedule of HTML 25K
Transactions with Related Parties (Tables)
30: R16 Equipment Disclosure: Change in book value of the HTML 24K
equipment (Tables)
31: R17 Revenue Disclosure: Schedule of Revenue and HTML 27K
Associated Costs (Tables)
32: R18 Notes and Advances Payable Disclosure: Schedule of HTML 31K
Short-term Loans and Advances Outstanding (Tables)
33: R19 Share Capital Disclosure: Schedule of Stock Option HTML 26K
Activity (Tables)
34: R20 Share Capital Disclosure: Schedule of Stock HTML 20K
Options Outstanding (Tables)
35: R21 Share Capital Disclosure: Schedule of Warrant HTML 26K
Activity (Tables)
36: R22 Share Capital Disclosure: Schedule of Warrant HTML 22K
Details (Tables)
37: R23 Organization and Nature of Operations (Details) HTML 20K
38: R24 Related Party Transactions Disclosure: Schedule of HTML 35K
Amounts Due to Related Parties (Details)
39: R25 Related Party Transactions Disclosure: Schedule of HTML 28K
Transactions with Related Parties (Details)
40: R26 Other Current Assets Disclosure (Details) HTML 20K
41: R27 Equipment Disclosure: Change in book value of the HTML 27K
equipment (Details)
42: R28 Revenue Disclosure: Schedule of Revenue and HTML 41K
Associated Costs (Details)
43: R29 Notes and Advances Payable Disclosure: Schedule of HTML 33K
Short-term Loans and Advances Outstanding
(Details)
44: R30 Notes and Advances Payable Disclosure (Details) HTML 56K
45: R31 Share Capital Disclosure (Details) HTML 32K
46: R32 Share Capital Disclosure: Schedule of Stock Option HTML 31K
Activity (Details)
47: R33 Share Capital Disclosure: Schedule of Stock HTML 20K
Options Outstanding (Details)
48: R34 Share Capital Disclosure: Schedule of Warrant HTML 25K
Activity (Details)
49: R35 Share Capital Disclosure: Schedule of Warrant HTML 23K
Details (Details)
52: XML IDEA XML File -- Filing Summary XML 87K
50: XML XBRL Instance -- cmxc-20211130_htm XML 614K
51: EXCEL IDEA Workbook of Financial Reports XLSX 41K
10: EX-101.CAL XBRL Calculations -- cmxc-20211130_cal XML 57K
11: EX-101.DEF XBRL Definitions -- cmxc-20211130_def XML 201K
12: EX-101.LAB XBRL Labels -- cmxc-20211130_lab XML 392K
13: EX-101.PRE XBRL Presentations -- cmxc-20211130_pre XML 335K
14: EX-101.SCH XBRL Schema -- cmxc-20211130 XSD 131K
53: JSON XBRL Instance as JSON Data -- MetaLinks 161± 227K
54: ZIP XBRL Zipped Folder -- 0001393905-22-000002-xbrl Zip 82K
| Loan Agreement October 7, 2021 |
LOAN AGREEMENT
Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced USD$15,000 (the “Principal Sum”) to Cell MedX (Canada) Corp. (the “Borrower”) of 820 - 1130 Pender Street West. Vancouver, BC V6E 4A4. The Lender advanced the funds on October 7, 2021. As per request of the Borrower, the Lender transferred the Principal Sum into the account of Cell MedX Corp., the Borrower’s parent corporation with an address at 123 W. Nye Ln, Suite 446, Carson City, NV 89706.
The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from October 7, 2021 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
| LENDER | BORROWER |
| Richard N. Jeffs | Cell MedX (Canada) Corp. |
|
|
|
| Per: | Per: |
|
|
|
|
|
|
| /s/ Richard N. Jeffs | /s/ Yanika Silina |
|
Richard N. Jeffs | Yanika Silina, Director |
PROMISSORY NOTE
| Principal Amount: USD$15,000 |
FOR VALUE RECEIVED Cell MedX (Canada) Corp., (the “Borrower”) promises to pay on demand to the order of Richard N. Jeffs (the “Lender”) the sum of $15,000 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum calculated from October 7, 2021 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
The Borrower acknowledges that, at the Borrower’s request, the Lender transferred the Principal Sum to Cell MedX Corp., the Borrower’s parent corporation.
The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
The Borrower waives presentment, protest, notice of protest and notice of dishonor of this promissory note.
BORROWER
Cell MedX (Canada) Corp.
Per:
/s/ Yanika Silina
Yanika Silina, Director
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 1/12/22 | None on these Dates | ||
| For Period end: | 11/30/21 | |||
| 10/7/21 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/15/24 Cell MedX Corp. 10-Q 2/29/24 53:2.7M Empire Stock Transf… Inc 1/16/24 Cell MedX Corp. 10-Q 11/30/23 46:2.3M Empire Stock Transf… Inc 10/16/23 Cell MedX Corp. 10-Q 8/31/23 42:1.9M Empire Stock Transf… Inc 9/01/23 Cell MedX Corp. 10-K 5/31/23 73:3.2M Empire Stock Transf… Inc 6/29/23 Cell MedX Corp. 10-Q 2/28/23 53:2.5M Empire Stock Transf… Inc 5/19/23 Cell MedX Corp. 10-Q 11/30/22 53:2.4M Empire Stock Transf… Inc 4/19/23 Cell MedX Corp. 10-Q 8/31/22 51:2.2M Empire Stock Transf… Inc 4/07/23 Cell MedX Corp. 10-K 5/31/22 90:3.6M Empire Stock Transf… Inc 4/11/22 Cell MedX Corp. 10-Q 2/28/22 56:2.5M Empire Stock Transf… Inc |